Company intelligence / Profile preview

GEOX

Smyrna, Georgia, United Statesgeox.com ↗

Ownership: Private
Development stage: Other

Overview

GeoVax has completed enrollment of its next-generation COVID‑19 vaccine candidate GEO-CM04S1 in several Phase 2 trials targeting both high-risk populations and as a heterologous booster. Its oncology program Gedeptin® has completed patient enrollment in a multicenter Phase 1/2 trial for advanced head & neck cancers. Additional pipeline assets target emerging infectious diseases including Mpox, smallpox, hemorrhagic fevers, malaria, and Zika; these are at earlier development stages.

Therapeutic areas: ImmunologyOncologyInfectious Diseases
Modalities: VaccineImmunotherapy
Industry: Biotech

Partnerships

Not specified in provided results. Publicly available information suggests collaborations with academic centers/hospitals for clinical trials but no major pharma partnerships listed here.

Beyond the preview

Go deeper on GEOX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GEOX.

Explore the full profile